InovIntell provides AI-powered decision-support solutions for the life sciences industry, with a focus on accelerating drug development and streamlining Health Technology Assessments. Their NaviHTA™ platform delivers data-driven insights and predictive intelligence to help organizations optimize market access strategies. The company combines machine learning, natural language processing, and life sciences expertise to build user-friendly tools for pharma, biotech, and academic research teams.
Funding
Funding not disclosed
Founders
Product
Problem
Life sciences organizations face increasingly complex regulatory and market access landscapes, requiring extensive manual analysis of clinical, economic, and regulatory data. Traditional approaches to Health Technology Assessments (HTA) and market access strategy are time-consuming, error-prone, and often fail to leverage the full potential of available data, leading to delayed product launches and suboptimal patient access.
Solution
InovIntell provides AI-empowered solutions that enhance decision-making throughout the drug development and evaluation process. Their proprietary NaviHTA™ platform delivers comprehensive HTA intelligence and strategic decision-making support, using data-driven insights and predictive intelligence to optimize market access strategies. The company combines three core expertise areas—digitization, AI/data science, and life sciences—to create tailored solutions that address regulatory, health economics, and medical affairs challenges. Their tools are designed to be user-friendly with an unobtrusive AI component, helping clients reach their goals faster and more efficiently.
Target Audience
Primary customers include pharmaceutical and biotech companies, academic research units, and pharmaceutical investors who need data-driven insights for drug development, regulatory approval, and market access optimization.
Features
- NaviHTA™ platform for comprehensive Health Technology Assessment intelligence and strategic market access planning
- Machine learning and natural language processing capabilities for analyzing complex regulatory and clinical data
- Proprietary digitization platform with ad hoc interactive communication tools for life sciences applications
- Predictive intelligence models that forecast market access outcomes and optimize strategic decisions
- Integration of health economics, regulatory affairs, and medical affairs expertise into AI-driven workflows
- Custom solution development for pharma, biotech, academic research, and investment organizations